Our COVID-19 vaccine, SCB-2019 (CpG 1018/Alum), has been authorized for emergency use in China. We are also developing candidates leveraging the Trimer-Tag™ technology and designed to be broadly protective against currently circulating and potential future strains of the SARS-CoV-2 virus.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
We have built our product pipeline by employing the Trimer-Tag™ technology platform.
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases